TSXV: ACB
VANCOUVER, April 20, 2017 /CNW/ - Aurora
Cannabis Inc. (the "Company" or "Aurora") (TSX-V: ACB) (OTCQX:
ACBFF) (Frankfurt: 21P; WKN:
A1C4WM) today announced that the Company has commenced sales of a
new product line of ingestible cannabis oils called Aurora
Drops.
The Company's newest offerings include three distinct product
types all priced equally at a standard flat rate of $115 per bottle, or $80 per bottle for clients approved for Aurora's
compassionate pricing program:
- THC Drops (Sativa) – a high potency THC oil extracted from
Cannabis Sativa flowers
- THC Drops (Indica) – a high potency THC oil extracted from
Cannabis Indica flowers
- CBD Drops – a high potency oil extracted from Aurora's flagship
CBD strain Temple (Cannatonic)
The Company's ingestible cannabis oils come in 30 ml glass
bottles with a child resistant certified cap and dropper to allow
for the easy and accurate dosing of small amounts of the high
potency fluids, and are produced using CGMP compliant supercritical
CO2 extraction technology, as well as using an MCT
carrier oil sourced from coconut oil.
As with all of Aurora's cannabis products, the test results from
the independent third-party lab for each batch of ingestible oil
are publicly available. Test results can be accessed online at
auroramj.com/strains, or through the Aurora Mobile app, a feature
rich mobile experience for iOs and Android that displays inventory
tracking and restocking events, and sends push notifications for
new product releases.
"The launch of our first ingestible oil products represents a
major milestone, which promises to add significantly to Aurora's
top and bottom line results," said Neil
Belot, Chief Global Business Development Officer. "We
have produced a sizeable inventory of Aurora Drops for our domestic
medical client base, and will be continuing to ramp up production
in order to address the strong demand we anticipate for
high-quality, high-margin derivative products, manufactured under
the rigorous Aurora Standards regarding processes, testing, and
transparency."
The Company recently signed a Memorandum of Understanding with
Radient Technologies Inc. ("RTI") with regards to the joint
development and commercialization in Canada of superior and standardized
cannabinoid extracts produced using RTI's high-throughput,
terpene-preserving, proprietary extraction technology.
"The strategic partnership with RTI has the potential to be a
game changer in this high-margin, high-growth segment of the
cannabis market, "said Terry Booth,
CEO. "If the technology works as we anticipate, Aurora will be able
to produce high volumes of terpene-rich cannabis derivatives at
lower costs and much shorter harvest-to-market times than any
company using current industry benchmark technologies. This would
give us an even stronger competitive advantage in what may well
become the dominant market segment. The launch of sales is the
first step in establishing our brand in the derivatives market, and
we are very pleased that we are able to expand our offering to a
customer base looking for alternative methods to consume
cannabis."
The companies' technical feasibility and commercial
opportunities study currently underway is proceeding well, and is
expected to be completed soon.
About Aurora
Aurora's wholly-owned subsidiary, Aurora Cannabis Enterprises
Inc., is a licensed producer of medical cannabis pursuant to Health
Canada's Access to Cannabis for Medical Purposes Regulations
(ACMPR). The Company operates a 55,200 square foot,
state-of-the-art production facility in Mountain View County,
Alberta, is currently
constructing a second 800,000 square foot production facility,
known as "Aurora Sky", at the Edmonton International Airport, and has
acquired and is undertaking completion of a third 40,000 square
foot production facility in Pointe
Claire, Quebec, near Montreal. In addition, the company is the
cornerstone investor with a 19.9% stake in Cann Group Limited, the
first Australian company licensed to conduct research on and
cultivate medical cannabis. Aurora's common shares trade on the
TSX-V under the symbol "ACB".
On behalf of the Board of Directors,
AURORA CANNABIS INC.
Terry Booth, CEO
These comments contain certain "forward-looking statements"
within the meaning of such statements under applicable securities
law. Forward-looking statements are frequently characterized by
words such as "plan", "continue", "expect", "project", "intend",
"believe", "anticipate", "estimate", "may", "will", "potential",
"proposed" and other similar words, or statements that certain
events or conditions "may" or "will" occur. These statements are
only predictions. Various assumptions were used in drawing the
conclusions or making the projections contained in the
forward-looking statements throughout this news release.
Forward-looking statements are based on the opinions and estimates
of management at the date the statements are made, and are subject
to a variety of risks and uncertainties and other factors that
could cause actual events or results to differ materially from
those projected in the forward-looking statements. The Company is
under no obligation, and expressly disclaims any intention or
obligation, to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise,
except as expressly required by applicable law.
The TSX Venture Exchange nor its Regulation Services Provider
(as that term is defined in the policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
SOURCE Aurora Cannabis Inc.